March 07, 2024

INmune Bio Demonstrates Significant Improvement in Alzheimer’s Disease Patients with Weekly XPro™ Treatment

Immunology company, INmune Bio, Inc. (Nasdaq: INMB) has demonstrated significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease (AD) treated with XPro™ for four weeks.  XPro™ works by reducing neuroinflammation to stop or slow the progression of cognitive and psychiatric symptoms of AD. CJ Barnum, PhD,… [Read More]
March 06, 2024

Neuronetics Reports Significant Growth in 2023, Expands Neurohealth Therapy Access; Shares Rise 23%

Neuronetics, Inc. (NASDAQ: STIM), a leading medical technology company specializing in neurohealth therapies, announced significant financial and operational achievements for the fourth quarter and the entire year of 2023. The company has seen substantial growth and strategic progress, reflecting its dedication to improving patient lives with advanced neurohealth therapies. Key Highlights Include: Q4 2023: Neuronetics… [Read More]
March 06, 2024

One-Stop EV Shop. GreenPower Rolls out Latest Innovation: GP Truck Body

GreenPower Motor Company Inc. (NASDAQ: GP) (TSXV: GPV), known for its all-electric, zero-emission medium and heavy-duty vehicles, has launched GP Truck Body, a new business unit aimed at providing commercial customers with a comprehensive one-stop shop for their vehicle needs. Key Highlights: Launch of GP Truck Body: A new entity focused on offering a wide… [Read More]
March 06, 2024

Meta Has Shown Entravision the Exit Amongst Other Advertisers, EVC Shares Drop 50%

Yesterday, PRISM AdTech and Media Index laggard, Entravision Communications (EVC) announced Q4 and FY2023 earnings that was mostly overshadowed by sharing Meta Platform’s (META) decision to wind down its global authorized sales partner (ASP) program, by July. While no comment was immediately made by Meta, Entravision mentioned in their announcement, the decision was communicated to… [Read More]
March 06, 2024

Lipella to Advance Oral Graft-versus-Host-Disease Candidate

 Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has received FDA approval of an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GvHD). Lipella expects to commence its clinical study in the second half of 2024. Dr. Jonathan Kaufman, CEO of Lipella, said, “We are extremely pleased to announce… [Read More]
March 06, 2024

Financial Markets Respond Positively as Powell Maintains Steady Fed Stance

In the latest financial market update, stock futures advanced and bond yields dipped following Federal Reserve Chair Jerome Powell’s reaffirmation that the Fed is not yet poised to reduce interest rates. During his prepared remarks to a House committee on Wednesday, Powell indicated that while the Fed anticipates it may start to lower borrowing costs… [Read More]